A U.S. Centers for Disease Control and Prevention (CDC) advisory committee on Friday recommended resuming use of the Johnson & Johnson coronavirus vaccine, saying the vaccine’s benefits outweigh the risk of severe cases of blood clots.
This decision opens the way in the United States to a possible lifting of the recommended suspension of the vaccine to a dose produced by the American laboratory. The Biden administration has said it will take the expert panel’s recommendations into account when determining the use of this vaccine. The panel voted 10 to 4 in favor of recommending the use of J & J’s vaccine for “persons 18 years of age and older in the US population, under emergency use clearance from the FDA (US Agency medication) “. A member of this body abstained.
Johnson & Johnson has said it supports adding a warning label on its vaccine, the formulation of which has been agreed with the FDA, the company noted. The FDA recommended on April 13 that the use of the J&J vaccine be stopped immediately, citing cases of a rare blood clot disorder that appeared in six women within two weeks of vaccination.
The CDC said on Friday that blood clots have been detected in at least nine other women, but the risk of people suffering from the disorder remains extremely low. Three women died from these rare blood clots and seven are still hospitalized, according to the same source.
Some 8 million doses of the Johnson & Johnson vaccine have been administered so far, according to the CDC.